State of Wyoming Makes New Investment in Krystal Biotech, Inc. $KRYS

State of Wyoming bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 4,767 shares of the company’s stock, valued at approximately $1,772,000.

Several other large investors have also modified their holdings of the business. Western Wealth Management LLC purchased a new stake in shares of Krystal Biotech in the 1st quarter worth approximately $34,000. Greenline Wealth Management LLC purchased a new position in Krystal Biotech during the fourth quarter valued at approximately $34,000. Danske Bank A S purchased a new position in Krystal Biotech during the third quarter valued at approximately $35,000. UMB Bank n.a. raised its stake in Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after buying an additional 37 shares in the last quarter. Finally, Global Retirement Partners LLC raised its stake in Krystal Biotech by 788.9% in the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after buying an additional 142 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $332.27 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The company has a market cap of $9.84 billion, a PE ratio of 41.64 and a beta of 0.53. The business has a 50-day simple moving average of $344.39 and a two-hundred day simple moving average of $299.25.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 7.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the transaction, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,642 shares of company stock worth $16,471,923 in the last three months. Corporate insiders own 13.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Citigroup upped their target price on Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. TD Cowen boosted their price target on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. HC Wainwright boosted their price target on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Chardan Capital upgraded Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, Krystal Biotech currently has a consensus rating of “Moderate Buy” and an average target price of $365.40.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.